Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
43 hedge funds and large institutions have $184M invested in Talis Biomedical Corporation Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 7 closing their positions.
4% less funds holding
Funds holding: 45 → 43 (-2)
5.53% less ownership
Funds ownership: 81.92% → 76.39% (-5.5%)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
32% less capital invested
Capital invested by funds: $269M → $184M (-$85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.81M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.75M |
| 3 |
BlackRock
New York
|
+$961K |
| 4 |
State Street
Boston,
Massachusetts
|
+$667K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.5M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.21M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.21M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.94M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.47M |
TLIS Hedge Fund Activity: Q2 2021 in Review
43 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q2 2021, worth a combined $184M — down 32% from $269M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TLIS and 5 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was Morgan Stanley, adding an estimated $4.81M. The largest seller was Federated Hermes, cutting an estimated $11.5M.
- 43 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q2 2021, down from 45 in Q1 2021.
- Funds reported $184M of Talis Biomedical Corporation Common Stock stock for Q2 2021, down 32% quarter-over-quarter.
- 5 funds opened new Talis Biomedical Corporation Common Stock positions in Q2 2021 and 7 closed out, a net change of -2 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q2 2021 was Morgan Stanley, an estimated $4.81M added.
- The largest Talis Biomedical Corporation Common Stock seller in Q2 2021 was Federated Hermes, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2021.